Analyst reviews leading mRNA COVID-19 vaccines candidates

17 December 2020

coronavirus_credit_deposit_photos-_largre

There are eight mRNA COVID-19 vaccine candidates currently in Phase II or Phase III clinical trials. These vaccines are faster to develop than traditional vaccine formulations, as they use only the genetic sequence of the virus.

Leading COVID-19 mRNA vaccine candidates reported greater than 90% efficacy, which raises concerns if other candidates in earlier stages of development can match that of the frontrunners, says analytics firm GlobalData.

Arcturus Therapeutics’ (Nasdaq: ARCT) potential single-dose vaccine ARCT-021 is reported to have demonstrated both humoral and cellular immunity to the vaccine antigen, at relatively low dose level, but it remains to be seen in future clinical trials whether the vaccine candidate can meet the high efficacy bar set by the frontrunners.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK